Glaukos Receives Permanent J-Code J2789 for Epioxa™ Ophthalmic Treatment, Effective July 2026

Key Takeaways

• CMS assigned permanent J-code J2789 to Glaukos’ Epioxa™ HD/Epioxa ophthalmic treatment, replacing temporary coding
• New coding system becomes effective July 1, 2026, potentially improving Medicare reimbursement access for patients
• This regulatory milestone supports broader market adoption of Epioxa™ for glaucoma and other eye conditions

---

Glaukos Corporation Secures Medicare Coding Victory

Glaukos Corporation (NYSE: GKOS) announced that the U.S. Centers for Medicare and Medicaid Services (CMS) has assigned a unique, permanent Healthcare Common Procedure Coding System (HCPCS) J-code for Epioxa™ HD/Epioxa. The new J-code, J2789, will become effective July 1, 2026.

Significance of Permanent J-Code Assignment

The assignment of a permanent J-code represents a crucial regulatory milestone for pharmaceutical products. J-codes are essential for healthcare providers to bill Medicare and other insurance programs for drug administration. Previously, Epioxa™ likely operated under a temporary or miscellaneous J-code, which can create reimbursement challenges and administrative burdens.

About Glaukos and Epioxa™

Glaukos Corporation specializes in ophthalmic pharmaceutical and medical technology solutions, focusing on novel therapies for glaucoma treatment, corneal disorders, and retinal diseases. The Aliso Viejo, California-based company has established itself as an innovator in minimally invasive glaucoma surgery (MIGS) and related ophthalmic treatments.

Epioxa™ represents part of Glaukos’ expanding portfolio targeting various eye conditions, though specific clinical applications and patient populations served by this treatment continue to drive market adoption.

Market Impact and Healthcare Access

Permanent J-code assignment typically facilitates:
- Streamlined billing processes for healthcare providers
- Improved reimbursement predictability for medical practices
- Enhanced patient access to innovative treatments
- Reduced administrative burden compared to miscellaneous coding

The July 2026 effective date provides healthcare systems adequate time to update billing systems and train staff on the new coding requirements.

Industry Context

The ophthalmic pharmaceutical market continues expanding as aging populations drive increased demand for glaucoma and retinal disease treatments. Permanent J-code assignments often signal CMS recognition of a drug’s established clinical utility and market presence.

For Glaukos investors and stakeholders, this regulatory achievement may support revenue predictability and market penetration strategies as the company continues developing its ophthalmic treatment portfolio.

---

Frequently Asked Questions

What does the permanent J-code mean for patients using Epioxa™?

The permanent J-code J2789 should improve insurance reimbursement processes and potentially reduce out-of-pocket costs by streamlining how healthcare providers bill for Epioxa™ treatments.

When will the new J-code J2789 for Epioxa™ take effect?

The permanent J-code J2789 for Epioxa™ HD/Epioxa will become effective on July 1, 2026, as announced by CMS.

How does permanent J-code assignment benefit Glaukos Corporation?

Permanent J-code assignment typically improves market access, reduces reimbursement uncertainty for providers, and can lead to increased adoption of Epioxa™ treatments in clinical practice.